Incyte Pharmaceuticals and Eli Lilly Expand Partnership to Explore Genetic Differences

Strategic Insights -

Incyte Pharmaceuticals, Inc. and Eli Lilly and Company have expanded their partnership to explore genetic differences, with Lilly becoming the first subscriber to Incyte's in silico SNP database. This agreement allows Lilly to access Incyte's LifeSeq(R) Gold sequence and expression database, which contains over 130,000 expressed genes. The partnership aims to aid researchers in understanding disease susceptibility and individual response to medication, using SNP's, single nucleotide polymorphisms, to understand genetic variations between individuals.

Key Takeaways:

  • Incyte's in silico SNP program uses a proprietary algorithm to discover common DNA sequence variants by mining Incyte's LifeSeq Gold database.
  • The database contains over 480 issued and allowed full-length gene patents and patent filings covering over 50,000 unique genes.
  • Eli Lilly will continue to have access to Incyte's extensive patent portfolio and will receive future milestone payments and royalties on sales of products developed with Incyte technology and database information.
  • Incyte's LifeSeq Gold sequence and expression database has been recognized as the most precise and comprehensive view of the human genome available.
  • The assembly process used by Incyte's LifeSeq Gold increases sensitivity in distinguishing closely-related sequences and organizes ESTs into a gene-centric rather than a sequence-centric database.
  • Incyte Pharmaceuticals is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease.

Statistics:

  • Over 130,000 expressed genes are represented in Incyte's LifeSeq Gold database.
  • The database contains over 480 issued and allowed full-length gene patents and patent filings covering over 50,000 unique genes.
  • Eli Lilly is the first subscriber to Incyte's in silico SNP database.

Sources:

  • "Incyte Pharmaceuticals and Eli Lilly Expand Partnership to Explore Genetic Differences" (press release citing Incyte Pharmaceuticals, Inc. and Eli Lilly and Company).
  • "(NYSE: LLY)".
  • "Incyte Pharmaceuticals, Inc." (www.incyte.com).
  • "Private Securities Litigation Reform Act of 1995".
  • Incyte Pharmaceuticals' Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.